Sellas Life Sciences Group, INC 8-K filings

SELLAS Life Sciences Group reported Q2 2026 results, highlighting progress in Phase 3 REGAL trial for GPS and Phase 2 for SLS009, with topline data expected Q4 2026, alongside a robust cash reserve of $138.3 million.

SELLAS Life Sciences Group, Inc. reported an estimated cash position of $138.3 million as of June 30, 2026, while also announcing an unfavorable arbitration decision regarding claims against 3D Medicines, Inc.

SELLAS Life Sciences Group has amended employment and severance agreements for its CEO, CFO, and Chief Development Officer.

SELLAS Life Sciences Group, Inc. reported on its Annual Meeting of Stockholders held on June 16, 2026, detailing voting outcomes on director re-elections, auditor ratification, equity plan amendments, executive compensation, and meeting adjournment.

SELLAS Life Sciences Group reports significant cash inflow from warrant exercises, bolstering its financial position.

SELLAS Life Sciences announced full-year 2025 financial results, reporting a strong cash position and significant progress in its pivotal Phase 3 REGAL trial and SLS009 clinical programs for AML.

SELLAS Life Sciences Group, Inc. reported an estimated $71.8 million in cash and cash equivalents as of December 31, 2025, supplemented by $26.5 million from warrant exercises.

SELLAS Life Sciences Group reported third quarter 2025 financial results, highlighted progress in its AML-focused pipeline, and announced a strengthened cash position.

SELLAS Life Sciences Group secured approximately $31 million in gross proceeds by inducing existing warrant holders to exercise their warrants, simultaneously issuing new warrants.

SELLAS Life Sciences Group, Inc. announced the extension of its New York City office sublease for an additional year, maintaining current annual rent.

SELLAS Life Sciences Group, Inc. announced a significant capital infusion of approximately $23.6 million from the cash exercise of existing warrants by an institutional investor.

SELLAS Life Sciences announced positive Q2 2025 financial results and significant clinical progress for its AML therapies, GPS and SLS009.

SELLAS Life Sciences Group, Inc. announced the results of its Annual Meeting of Stockholders held on June 17, 2025, where all proposals, including director re-elections, auditor ratification, and an increase in shares for the Employee Stock Purchase Plan, were approved.

SELLAS Life Sciences Group, Inc. announced the appointment of Baker Tilly US, LLP as its new independent registered public accounting firm, effective June 3, 2025, following the merger of its previous auditor, Moss Adams LLP, with Baker Tilly.

SELLAS Life Sciences reports positive survival data from its SLS009 trial in AML, promising preclinical results, and a cash position of $28.4 million as of March 31, 2025.

SELLAS Life Sciences reports positive interim analysis for its Phase 3 REGAL trial in AML and provides a corporate update, including full year 2024 financial results.

SELLAS Life Sciences Group has entered into a securities purchase agreement for a $25 million registered direct offering with a healthcare-focused institutional investor.

SELLAS Life Sciences' Phase 3 REGAL trial of galinpepimut-S (GPS) in acute myeloid leukemia (AML) successfully passed its interim analysis, with the Independent Data Monitoring Committee (IDMC) recommending continuation of the trial without modification.

SELLAS Life Sciences Group has amended change in control severance agreements for two senior executives, providing for 15 months of base salary upon termination related to a change of control.

SELLAS Life Sciences has announced the triggering of an interim analysis in its Phase 3 REGAL trial for galinpepimut-S (GPS) in acute myeloid leukemia (AML) after reaching a pre-specified threshold of 60 events (deaths).

SELLAS Life Sciences announced its third quarter 2024 financial results and provided a corporate update, highlighting progress in its clinical trials and regulatory designations.

SELLAS Life Sciences Group has extended its office sublease at Times Square Tower in New York City by one year, now expiring on September 30, 2026.

SELLAS Life Sciences reported positive preliminary data from its SLS009 trial in AML, secured $21 million in funding, and received a recommendation to continue its Phase 3 REGAL study.

SELLAS Life Sciences has successfully raised approximately $21 million through a registered direct offering of common stock and warrants.

SELLAS Life Sciences Group held its annual meeting, re-electing directors, ratifying its auditor, and approving an advisory vote on executive compensation.

SELLAS Life Sciences announced positive clinical trial updates for its lead drug candidates and reported its first quarter 2024 financial results.

SELLAS Life Sciences announced positive clinical trial results for its drug candidates and reported its full year 2023 financial results, highlighting progress in its late-stage pipeline.

SELLAS Life Sciences' partner, GenFleet, has begun a clinical trial combining their CDK9 inhibitor with a BTK inhibitor for lymphoma treatment.

SELLAS Life Sciences Group has entered into agreements for a $20 million registered direct offering and concurrent private placement of common stock and warrants.

SELLAS Life Sciences Group has regained compliance with Nasdaq's minimum bid price requirement after its stock price closed above $1.00 for ten consecutive days.